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Abstract 
 
Cationic macromolecular carriers can be effective carriers for small molecular compounds, drugs, 
epitopes or nucleic acids. Polylysine based polymeric branched polypeptides have been 
systematically studied on the level of cells and organisms as well. In the present study we report 
on our findings on the cellular uptake characteristics of nine structurally related polylysine based 
polypeptides with cationic side chain composed of   i)   single   amino acid (poly[Lys(Xi)], XiK) 
or ii)   oligo[DL-alanine]   (poly[Lys(DL-Alam)], AK) or iii) oligo[DL-alanine] with an additional 
amino acid (X) at terminal position (poly[Lys(Xi-DL-Alam)] (XAK)) or iv) at the position next to 
the polylysine backbone ((poly[Lys(DL-Alam-Xi)] (AXK)). In vitro cytotoxicity and cellular 
uptake were characterized on HT-29 human colon carcinoma and HepG2 human 
hepatocarcinoma cell lines. Data indicate that the polycationic polypeptides studied are 
essentially non-toxic in the concentration range studied and their uptake is very much dependent 
on the side chain structure (length, identity of amino acid X and on the distance between the 
terminal positive charge) and also on the cell lines. Our findings in uptake inhibition studies 
suggest that predominantly macropinocytosis and caveole/lipid raft mediated endocytosis are 
involved. The efficacy of their internalization is markedly influenced by the hydrophobicity and 
charge properties of the amino acid X. Interestingly, the uptake properties of the these 
polypeptides show certain similarities to the entry pathways of several cell penetrating peptides.  
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Introduction 
 
Polymers including peptide based carriers are widely used for the delivery of bioactive molecules 
like antitumor agents1-3, B- and T-cell epitope peptides4, 5 or therapeutic macromolecules such as 
siRNA6. Coupling small molecular cytotoxic drugs e.g. daunomycin to a macromolecule can 
improve solubility, decrease side effects and can give a chance for cell or tissue specific targeting 
in vivo7. Considering that the tumor vasculature is more permeable and the lymphatic system is 
not as well developed as the lymphatic system of the healthy tissues, macromolecules are able to 
accumulate selectively in the tumor8, 9 but not in the healthy tissues. The cationic macromolecule 
polylysine and its derivatives proved to be feasible for nucleic acid delivery over the years – 
including DNA10-12, siRNA13 and microRNA.14 Polylysine based branched polypeptides could be 
effective carriers for drugs like daunomicin 7, 15, methotrexate 16, 17 as well as T cell or B cell 
epitope peptides 18, 19. This group of polymeric polypeptides was methodically investigated on the 
level of the organism: toxicity 3, 20, blood survival 20, biodistribution 21, 22; immunogenicity 23, 
immunomodulatory effect 24 as well as at cellular level: in vitro cytotoxicity 3 and chemotaxis 25 
were studied. Interaction of the polypeptides with phospholipid bilayers was also examined. 26, 27 
Results of these studies showed that the length and amino acid composition of the side chains 
attached to the poly[L-Lys] backbone and the charge of the terminal amino acid can determine 
the biological and physico-chemical properties of the polypeptides and also that of their 
drug/epitope conjugates. On cellular level we recently demonstrated that poly[L-Lys] based 
branched polypeptides with different charge properties are taken up effectively by the J774 
macrophage like cell line and also by bone marrow macrophages. Polyanionic polypeptides 
entered the cells via class A scavenger receptor 25, 28, while the polycationic and amphoteric 
polypeptides most likely have no recognition structure on the cell surface. Although the cellular 
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uptake of daunomycin–polypeptide conjugates have already been studied and it was established 
that these conjugates, as well as corresponding free polypeptides, are internalized into murine 
macrophages and murine and human cell lines 29 and HL-60 human leukemia cells 30, we know 
little about the mechanism of the internalization.  
In the present study we examined the cellular uptake characteristics of nine structurally related 
polylysine based polypeptides with cationic side chains consisting of a single amino acid  (X) 
(poly[Lys(Xi)], XiK) or an oligo[DL-alanine] side chain (poly[Lys(DL-Alam)], AK) or oligo[DL-
alanine] side chains with an additional amino acid X at the N-terminal position (poly[Lys(Xi- DL-
Alam)], XAK) or at position next to the polylysine backbone (poly[Lys(DL-Alam-Xi)], AXK) 
(Figure 1.). Here we report on our findings on in vitro cytotoxicity and cellular uptake of the 
polypeptides on two tumor cell lines of different origin: HT-29 human colon carcinoma and 
HepG2 human hepatocarcinoma cells. In addition, we also describe the results of a study 
concerning the cellular uptake mechanism of these polycationic compounds with different side 
chain architecture. By using a set of endocytic inhibitors we intended to clarify the type(s) of 
endocytic mechanisms potentially involved in the uptake. Data suggest that the polycationic 
polypeptides studied are essentially non-toxic in the concentration range studied, but their uptake 
is very much dependent on the side chain structure, length of the side chain, and identity of amino 
acid X and on the distance between the backbone and the terminal positive charge, and also on 
the cell lines. Our findings also suggest that macropinocytosis and caveole/lipid raft mediated 
endocytosis are typically involved in the uptake of the cationic polymeric polypeptides.   
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Figure 1.  Schematic chemical structure of polylysine and polylysine based branched 
polypeptides with different side chain composition (m=1-4). The figure shows one representative 
of each type of polypeptides: XiK (poly[Lys(Xi)] type HiK, where X=His; AK (poly[Lys(DL-
Alam)], AXK (poly[Lys(DL-Alam-Xi] type ALK, where X=Leu and XAK (poly[Lys(Xi-DL-Alam]) 
type RAK, where X=Arg. 
 
Results and Discussion 
 
Branched polypeptides with the general formula poly[Lys(Xi)], poly[Lys(DL-Alam)], poly[Lys(Xi-
DL-Alam)] or poly[Lys(-DL-Alam-Xi)] (m≅3, i≅1) were investigated. The common feature of the 
group studied is their cationic charge properties. However, the polypeptides varied in the length 
of their side chain, the identity of the terminal amino acid and/or in the position of amino acid X 
in relation to the poly[Lys] backbone. First we studied the in vitro cytotoxicity of the compounds. 
This was followed by the analysis of the level of the cellular uptake and the intracellular 
localization of carboxyfluorescein labeled polypeptides in two different cell lines. The uptake 
mechanism of selected compounds with elevated ingestion was investigated by applying four 
different inhibitors related to various forms of endocytosis. 
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In vitro cytotoxicity  
Cytotoxicity of the unlabeled cationic polypeptides was determined at the concentration range of 
6.25 µg/mL-100 µg/mL by MTT assay. Results are expressed as a percentage of untreated cells 
and after that, LC50 values were determined as shown in Table 1. Results indicate that only 
poly[Lys] was toxic both on HT-29 and HepG2 cells (LC50=44.1±4.6 µg/mL and  32.3±10.8 
µg/mL, respectively). 
LC50 [µg/mL] (SD)f 
Polypeptidea Codeb DPnc Mwd Cf [%]e 
HT-29 HepG2 
poly[Lys] - 130 17000 15.5 44.1(4.6) 32.3(10.8) 
poly[Lys(Pro0.95)] PiK 84 18400 18.6 >100 >100 
poly[Lys(His0.56)] HiK 93 18900 8.7 >100 >100 
poly[Lys(Leu0.92)] LiK 80 18500 10.5 >100 >100 
poly[Lys(DL-Ala3.9)] AK 60 24200 10.5 >100 >100 
poly[Lys(Ser1.0- DL-Ala3.8)] SAK 60 29400 2.4 >100 >100 
poly[Lys(Thr0.9- DL-Ala3.8)] TAK 60 29300 14.0 >100 >100 
poly[Lys(DL-Ala3.0-Leu0.97)] ALK 80 34800 21.7 >100 >100 
poly[Lys(Arg0.57-DL-Ala3.9)] RAK 60 29800 1.3 >100 >100 
Arg8 R8 - - 23.2   
Table 1 Chemical characteristics and cytotoxicity of polylysine based branched chain 
polymeric polypeptides with poly[Lys(Xi)],  poly[Lys(Xi-DL-Alam)] or  poly[Lys(DL-Alam-
Xi)] formula.  
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aAmino acid composition was determined by amino acid analysis following hydrolysis in 6M 
HCl at 105°C for 24 hours; 
bCode of branched chain polymeric polypeptides, based on one-letter symbol of amino acids;  
cAverage degree of polymerization determined by sedimentation equilibrium measurements; 
dAverage molecular mass of each polypeptide was calculated from the average degree of 
polymerization of poly[Lys] and of the side chain composition 
eAverage degree of substitution (m/m%) for 5(6)-carboxyfluorescein (Cf) was determined by 
UV spectrophotometry at λ = 492 nm. 
fLC50 values (SD) were determined by fitting a sigmoid (logistic) curve on the cytotoxicity 
data with Microcal Origin 9.2   
 
Cellular uptake 
Concentration dependence 
Concentration dependence of the uptake of fluorescently labeled polypeptides was examined by 
flow cytometry. Cells were treated with the polypeptides at 0.1, 1, 10, 50 and 100 µg/mL 
concentrations. Earlier we investigated the kinetics of the internalization of Cf-polypeptides on 
J774 monocyte cell line. 25 Based on that results, we chose 60 minutes as the duration of the 
treatment. We observed that the uptake of the compounds increased by the elevation of the 
concentration in both cell lines. However, the dynamics and the level of internalization at a given 
concentration varied markedly.  In case of HT-29 cells, Cf-RAK and Cf-PiK polypeptides were 
internalized at 50 and 100 µg/mL concentrations, respectively. Whereas Cf-HiK, Cf-LiK, Cf-AK, 
Cf-SAK Cf-ALK and Cf-poly[Lys], polypeptides were ingested already at 10 µg/mL. Uptake of 
CPP Cf-Arg8 was more effective (it was significant from 0.1 µg/mL). (Table 2).  In order to 
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compare the efficacy of the uptake we calculated fluorescence mean data normalized to 
carboxyfluorescein content of each polypeptide (Figure 2A). According to these values, the 
uptake of Cf-Arg8 was comparable to the polypeptides; at 50 µg/mL the most effective uptake 
was observed as follows: Cf-HiK>Cf-LiK>Cf-RAK~Cf-SAK>Cf-AK>Cf-poly[Lys]>Cf-ALK. 
The internalization profile of HepG2 cells was slightly different. Cf-RAK polypeptide entered the 
cells at 50 µg/mL, while Cf-HiK, Cf-PiK, Cf-SAK, Cf-ALK and poly[Lys] polypeptides were 
taken up from 10 µg/mL concentration, whereas the most effective polypeptides, Cf-LiK and Cf-
AK elicited an uptake already at 1 µg/mL concentration as well as Cf-Arg8 peptide (Table 3). 
According to data normalized to Cf content of each polypeptide, the following order of the 
uptake could be observed at 50 µg/mL concentration: Cf-LiK>Cf-RAK>Cf-HiK~Cf-AK>Cf-
poly[Lys]>Cf-ALK (Figure 2B). Essentially no (Cf-TAK) or minimal (Cf-PiK) uptake was 
observed on either of the cell cultures. The comparison of the uptake by the two cell lines 
indicates some similarities. Namely, the most engulfed three polypeptides (Cf-LiK, Cf-HiK, and 
Cf-RAK) and the least ingested polypeptides (Cf-PiK, Cf-TAK) were identical. 
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c [µg/mL]  Cf-labeled 
(Poly)peptide 0.1 1 10 50 100 
poly[Lys] 1 (0) 32 (4) 1662 (79)* 4487 (238)* 7470(105)* 
HiK 113 (129) 49 (8) 4741 (376)* 11946 (65)* 14095 (1082)* 
PiK 2 (0) 78 (9) -1 (1) 36 (14) 2139 (97)* 
LiK 9 (4)  39 (17)   566 (88)* 8991 (467)* 23332 (467)* 
AK 2.5 (1.4) 14.5 (1.4) 703.5 (29.7)* 4066.5 (99)* 7349 (124)* 
SAK 0 (1) 4 (1) 461 (30)* 1406 (6)* n.d. 
TAK -1 (1) 0 (1) 4 (0) 10 (1) 36 (18) 
ALK 9 (5) 30 (1) 575 (54)* 2757 (34)* 5379 (214)* 
RAK 1 (1) 2 (4) 63 (12) 845 (91)* 3050 (303)* 
Arg8 9(0)* 214 (0)* 5551 (373)* 48259 (991)* 68895(2971)* 
Table 2 Uptake of the fluorophore (Cf)-labeled polycationic polypeptides and cell 
penetrating peptide Arg8 by HT-29 cells after 60 minutes. Data represent the average of mean 
fluorescence values (SD) of a representative experiment of two independent assays after 
subtracting the control. Statistical analysis of data was performed by Student’s t-test of Origin 
9.2 (* p<0.05). 
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c [µg/mL]  Cf-labeled 
(Poly)peptide 0.1 1 10 50 100 
poly[Lys] -3 (1) 44 (18) 1489 (1)* 6584 (1048)* 9346 (308)* 
HiK 8 (8) 185 (194) 1717 (28)* 4945 (1488)* 13596(740)* 
PiK -22 (11) 17 (4) 337 (40)* 745 (102)* 1242 (70)* 
LiK 47 (7) 140 (18)* 1501 (305)* 8570 (94)* 13146(290)* 
AK 2 (2) 76 (1)* 1897 (36)* 6582 (59)* 9354 (235)* 
SAK -4 (1) 12 (1) 106 (11)* 100 (11)* 554 (58)* 
TAK -3 (1) -3 (4) 3 (4) 24 (1) 45 (1)* 
ALK 1 (6) 2 (1) 418 (39)* 7043 (2553)* 16786(1963)* 
RAK 1 (0) 12 (2) 274 (49) 1006 (222)* 2639 (780)* 
Arg8 4,5 (2) 390 (17)* 4577 (405)* 10663 (774)* 15976 (214)* 
Table 3 Uptake of the fluorophore (Cf)-labeled polycationic polypeptides and cell 
penetrating peptide Arg8 by HepG2 cells after 60 minutes. Data represent the average of mean 
fluorescence values (SD) of a representative experiment of two independent assays after 
subtracting the control. Statistical analysis of data was performed by Student’s t-test of Origin 
9.2 (* p<0.05). 
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Figure 2. Concentration dependence of the uptake of the Cf-labeled polypeptides by HT-29 (A) 
and HepG2 (B) cells after 60 minutes. Symbols represent the average of normalized mean 
fluorescence values ± SD of two independent assays. Data were normalized to 
carboxyfluorescein content of each Cf-(poly)peptide. : 100 µg/mL, : 50 µg/mL, : 10 
µg/mL 
 
Intracellular localization  
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Intracellular localization of the labeled polypeptides was investigated by confocal laser scanning 
microscopy. Cells were treated with the Cf-polypeptides at 100 µg/ml and with Cf-Arg8 at 50 
µg/ml concentration for 60 minutes. Results indicated that Cf-polypeptides could be detected 
within the cells; most of the compounds were localized in vesicles in the cytoplasm of the living 
cells. Cf-poly[Lys] could be observed also in the nucleus in case of both cell lines (Figure 3 and 
4), partly in dead cells in the samples due to the toxicity of the compound. Cf-HiK also was 
localized in the nuclei of HepG2 cells (Figure 4). Different type of vesicles could be observed 
depending on the side chain composition of the polypeptides and also on the cell type. In HT-29 
cells, cationic and hydrophobic Cf-HiK and Cf-LiK polypeptides were localized in small vesicles 
in the cells (Figure 3).  Vesicles of Cf-ALK could be observed mostly at the plasma membrane, 
which suggests slower uptake of this polypeptide. Larger vesicles like in case of LiK, AK and 
ALK may appear due to the aggregation of the polypeptides following of prior to the uptake. 
 
Figure 3 Intracellular localization of Cf-polypeptides (green) in HT-29 human colon 
carcinoma cells (c=100 µg/mL) after 60 minutes. Cells were fixed with 4% paraformaldehyde in 
PBS (pH 7.4). Membrane structures were labeled with DiD perchlorate (red). Each bar 
represents 10 µm.  
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In case of HepG2 cells, Cf-ALK polypeptides showed a more diffuse pattern in the cytoplasm 
compared to HT-29 cells, whereas vesicles containing Cf-AK were localized at the plasma 
membrane. 
 
Figure 4.  Intracellular localization of Cf-polypeptides (green) in HepG2 human 
hepatocarcinoma cells (c=100 µg/mL) after 60 minutes. Cells were fixed with 4% 
paraformaldehyde in PBS (pH 7.4). Membrane structures were labeled with DiD perchlorate 
(red). Each bar represents 10 µm. 
 
The intracellular localization of Arg8 peptide at c=50 µg/mL concentration was different from 
that of the polypeptides. The CPP was observed in the nucleus as well as diffusely in the 
cytoplasm in both cell lines (Figure 3 and 4). 
 
Endocytosis inhibition 
In order to shed light on the mechanism of the internalization of the polypeptides, cells were pre-
treated with colchicine, the inhibitor of pinocytosis 31, MβCD, inhibitor of caveole/lipid raft 
mediated endocytosis 32, EIPA and cytochalasin D for inhibiting macropinocytosis 33, 34. These 
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experiments were performed on both cell lines, but only with polypeptides that elicited an 
effective internalization (Cf-poly[Lys], Cf-HiK, Cf-LiK, Cf-AK, Cf-ALK and Cf-RAK) and 
poly[Lys] a control. A different inhibition pattern could be observed in case of the two cell lines. 
Uptake of some Cf-polypeptides by HT-29 was significantly inhibited by cytochalasin D (Figure 
5A) and by MβCD (Figure 5C), but essentially no inhibition of the ingestion of any studied 
polypeptide was observed after treatment of the HT-29 cells with EIPA (Figure 5B) or colchicine 
(Figure 5D). Inhibition of the uptake both by cytochalasin D (Figure 5A) and by MβCD (Figure 
5C) was marked for Cf-HiK and for Cf-AK. It is interesting to note that only cytochalasin D 
blocked the uptake of Cf-LiK and Cf-AK (Figure 5A) and only MβCD was capable to prevent the 
process with Cf-poly[Lys] to some extent (Figure 5C).  In case of HepG2 cells, only Cf-HiK 
showed a decreased uptake by the cells pre-treated with more than one inhibitor (cytochalasin D) 
(Figure 6A), EIPA (Figure 6B) and MβCD (Figure 6C). It should be noted that cytochalasin D 
was also capable to influence the internalization of Cf-LiK, Cf-RAK and Arg8 peptide (Figure 
6A). Similarly to the findings with HT-29 cells no effect on polypeptide uptake could be 
observed after administration of colchicine (Figure 6D). Inhibition data are summarized in Table 
4. Based on the comparative analysis of the results we can presume that macropinocytosis is 
involved in the uptake of Cf-HiK, Cf-LiK, Cf-AK and Cf-ALK polypeptides by HT-29 colon 
carcinoma cells. Results indicate that caveole/lipid raft mediated endocytosis can be involved in 
the internalization of Cf-poly[Lys], Cf-HiK, and Cf-ALK by HT-29 cells. Thus combined 
mechanism (macropinocytosis + caveole/lipid raft mediated endocytosis) could be considered in 
case of polypeptides HiK and ALK, while the most positively charged polypeptide, RAK can be 
engulfed mainly by the caveole/lipid raft mediated endocytosis. In case of HepG2 cell line, 
macropinocytosis as well as caveole/lipid raft mediated endocytosis can both play a role in the 
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uptake of Cf-HiK polypeptide, whereas Cf-LiK and Cf-RAK polypeptides may enter HepG2 cells 
predominantly by macropinocytosis. In several cases pre-treatment of the cells with the 
endocytosis inhibitors resulted in a significant increase in the uptake (e.g. Arg8 peptide and AK 
polypeptide in the presence of EIPA and cytochalasin D or LiK polypeptide in the presence of 
EIPA in case of HT-29 cells showed a more pronounced uptake compared to their uptake without 
inhibitor. These results also suggest that not a single mechanism mediates the internalization of a 
compound, as one endocytic route is inhibited, other pathways can be activated. 
 
Figure 5 Uptake of the Cf labeled polypeptides and Arg8 by HT-29 cells in the presence of 
endocytosis inhibitors. Columns represent the average of mean fluorescence values of a 
representative experiment of two independent assays ± SD after subtracting the control. Black 
columns: internalization of the Cf-polypeptides ((c=100 µg/mL, Cf-poly[Lys]: c= 50 µg/mL)) 
and Cf-Arg8 (R8, c=50 µg/ml) without inhibitor; grey columns: internalization in the presence of 
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A: cytochalasin D (5 µg/ml), B: EIPA (75 µM), C: MβCD (2.5 mM), D: colchicine (10 µM). 
Statistical analysis of data was performed by Student’s t test; *: p<0.05. 
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Figure 6. Uptake of the Cf labeled polypeptides and Arg8 by HepG2 cells in the presence of 
endocytosis inhibitors. Columns represent the average of mean fluorescence values of a 
representative experiment of two independent assays ± SD after subtracting the control. Black 
columns: internalization of the Cf-polypeptides (c=100 µg/mL, Cf-poly[Lys]: c= 50 µg/mL) and 
Cf-Arg8 (R8, c=50 µg/ml) without inhibitor; grey columns: internalization in the presence of A: 
cytochalasin D (5 µg/ml), B: EIPA (75 µM), C: MβCD (2.5 mM), D: colchicine (10 µM). 
Statistical analysis of data was performed by Student’s t test; *: p<0.05. 
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Several cationic oligopeptides like bradykinin 35 or the opioid peptide TAPA 36 are recognized by 
specific cell surface receptors. Internalization of other cationic peptides including cell penetrating 
oligopeptides was also thoroughly investigated. No single and well defined mechanism was 
determined so far, but in some cases multiple uptake mechanisms were reported 37-39. Among the 
entry pathways several passive as well as endocytic mechanisms were described: 
macropinocytosis, lipid raft or clathrin mediated processes were equally proposed 40, 41. Several 
endocytic mechanisms were studied by Lühmann et al. in case of poly[Lys] containing (PLL-g-
PEG-DNA) nanoparticles: it was established that the uptake of these constructs is energy 
dependent and endocytic inhibitors could elicit some decrease in the uptake, but no single 
classical endocytosis pathways could be defined 42.  In the present study we analyzed the uptake 
of a structurally related group of polymeric polylysine based polypeptides. We investigated if 
polypeptides enter two human tumor cell lines, HT-29 colon carcinoma and HepG2 
hepatocarcinoma, via endocytosis and we also tried by using appropriate inhibitors to find 
similarities in the mechanism of internalization with cell penetrating peptides already studied. 
Our data indicate that the efficacy of the internalization can be influenced by the composition of 
the side chain, and hydrophobicity and charge properties of the amino acid X and perhaps by the 
distance of the positively charged groups from the backbone. The polypeptides most effectively 
internalized contained a positively charged αNH2-group and another cationic group (imidazole 
group in HiK and guanidino group in RAK polypeptide) in their side chains or a positively 
charged αNH2-group and hydrophobic amino acid (Leu in LiK) next to the polylysine backbone. 
In case of PiK polypeptide, which contains an imino group (instead of αH2N-group) in its side 
chain; polypeptides TAK and SAK carrying a hydrophilic terminal amino acid and polypeptide 
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ALK with an αNH2-group at the side chain terminal position, at a longer distance from the 
backbone, the uptake was much less pronounced. Taken together, those polypeptides elicited the 
most effective uptake, that carry more than one  positively charged group in their side chains 
close to the polylysine backbone. The uptake of the polypeptides proved to be the same order of 
magnitude as CPP Arg8 applied as a positive control. 
The mechanism of the uptake proved to be dependent also on the cell type. Most of the cationic 
polypeptides entered HT-29 cells via macropinocytosis or lipid raft mediated endocytosis. 
Internalization of Arg8 peptide was inhibited slightly by cytochalasin D in case of HT-29 cells. 
We could observe a multiple mechanism in case of Cf-HiK in case of HepG2 cells, which could 
explain the effective cellular uptake of this polypeptide.  Two other polypeptides, LiK and RAK 
enter the cells seemingly by macropinocytosis. Direct translocation of some polylysine based 
polypeptides cannot be excluded however, especially that of poly[Lys] and the HiK polypeptide, 
and especially of Arg8 peptide, which were detected in the nuclei.  
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HT-29 HepG2 
Polypeptide 
colchicine EIPA cytochalasin D MβCD colchicine EIPA cytochalasin D MβCD 
poly[Lys] ∅ ∅ ∅ - ∅ ∅ ∅ ∅ 
HiK ∅ ∅ - - ∅ - - - 
LiK ∅ ∅ - ∅ + + - ∅ 
AK ∅ ∅ - ∅ + + ∅ + 
ALK ∅ ∅ - - ∅ ∅ ∅ ∅ 
RAK ∅ ∅ ∅ - ∅ ∅ - ∅ 
Arg8 ∅ + + ∅ ∅ ∅ - ∅ 
Table 4  Effect of endocytosis inhibitors on the uptake of polylysine based cationic polypeptides and Arg8 by HT-29 
human colon carcinoma and HepG2 human hepatocarcinoma cell lines. (∅: no inhibition, -: reduced uptake, +: 
increased uptake) 
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Coupling different cargos to the carrier polypeptides can also influence the rate and presumably 
the mechanism of the internalization. In our earlier studies we observed a different rate of the 
uptake of a daunomycin containing conjugate (cAD-SuccEAK, poly[Lys(SuccGlu-DL-Alam)]) 
and the carboxyfluorescein-labeled polypeptide (Cf-SuccEAK). 29 
Similarly to the polylysine based polypeptides studied by our group, lipid raft mediated 
endocytosis and macropinocytosis have been described as the mechanism of the internalization in 
case of a Qdot-R9 conjugate 39 as well as in case of luciferin-CPP conjugates. 43, 44 Molecular 
constructs consisting of polymeric, but non-peptidic carrier and cell penetrating peptide have 
been shown before to bear cell penetrating properties due to their CPP content.45 Therefore it is 
important to mention that to the best of our knowledge no systematic studies were reported so far 
on the uptake characteristics of polymeric polypeptides. Our findings suggest that cationic 
polypeptides could exhibit cell penetrating properties themselves, without the attachment of 
CPPs. These cationic polylysine based polymeric polypeptides can be promising candidates of 
further investigations for example in comparative studies with CPP oligopeptides in order to 
understand the similarities and differences to be utilized for the development of bioconjugates 
containing chemotherapeutic agents (e.g. antitumor, antimicrobial) or epitopes (e.g. for synthetic 
vaccines) and cationic polypeptide carriers that can be able to transport small molecules into the 
cells. 
 
Experimental Procedures 
 
Reagents 
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Amino acids, HCl and DMF were purchased from Reanal and Molar Chemicals (Budapest, 
Hungary). Pentachlorophenol, 1-hydroxybenzotriazole, triethylamine, and DMSO were from 
Fluka (Buchs, Switzerland), acetonitrile was from Merck (Darmstadt, Germany). FCS was 
obtained from Gibco Brl. and from Sigma-Aldrich (Budapest, Hungary). MTT, 5(6)-
carboxyfluorescein succinimid ester, 0.4% trypan blue solution, RPMI-1640 medium powder, 
glutamine, gentamycin, chemicals for buffers and eluents were from Sigma-Aldrich (Budapest, 
Hungary). DiD perchlorate was from R&D Systems (Minneapolis, MN, USA). 
 
Polypeptides 
Synthesis of poly[Lys(Xi)],(XiK), poly[Lys(Xi-DL-Alam)], (XAK) and poly[Lys(-DL-Alam-Xi), (AXK)  
type polypeptides 
Poly[Lys(Xi)] (XiK) where X=His, Leu or Pro, XAK-type polypeptides where X=Arg, Ser or Thr 
were prepared and characterized according to Mező et al. 46, 47 Briefly, in case of XiK and AXK 
polypeptides, amino acid X was coupled to the εNH2-groups of polylysine as Z-X-OPcp, where 
X=Pro, His or Leu. The coupling reaction was carried out by in situ active ester method using an 
equivalent amount of 1-hydroxybenzotriazole (HOBt) dissolved in DMF as activating reagent. 
Poly[Lys(DL-Alam)], (AK) were synthesized by grafting short oligomeric DL-Ala chains to the 
εNH2 group of lysine residues using N-carboxy-DL-Ala-anhydride. Polymerization was continued 
at room temperature for 2 days. Terminal amino acids (X) were coupled to the αNH2-groups of 
the terminal alanine residues of the oligo-alanine chains as Z-X-OPcp, where X=Arg, Ser or Thr. 
The polypeptides were purified by dialysis against distilled water for two days using Visking tube 
(cutoff = 12000-14000 Da) and isolated by freeze-drying. Amino acid composition of the 
polymeric polypeptides was determined by amino acid analysis in a Beckman 6300 analyzer 
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(Fullerton, CA) (poly[Lys], PiK, HiK, AK, TAK, SAK and ALK) or in a Sykam Amino Acid 
S433H analyzer (Eresing, Germany) (LiK, RAK) Prior to the analysis, the samples were 
hydrolyzed in 6 M HCl in sealed and evacuated tubes at 105°C for 24 hours. 
 
Labeling of polymeric polypeptides with 5(6)-carboxyfluorescein 
10 mg (6×10-7 – 1.9×10-7 mol) polypeptides were dissolved in 2 mL sodium-carbonate buffer 
(0.1M; pH 9.4). 5(6-)carboxyfluorescein succinimid ester was added to the polypeptide solution 
dissolved in DMSO (c=10 mg/mL, 0.21 mM) in aliquots with continuous stirring. The reaction 
was continued for 1 hour at room temperature. The labeled polypeptide was purified on PD10 
column filled with Sephadex G25 with distilled water as eluent, then freeze-dried.28 
Carboxyfluorescein content of the samples was determined by a UV spectroscopy using a Perkin 
Elmer Lambda 2S UV/VIS Spectrometer at λ=492 nm. 
 
Functional studies 
 
Cell culturing 
HT-29 human colon carcinoma (ATCC HB-8065) and HepG2 (ATCC HTB-38) human 
hepatocellular carcinoma cell-lines were maintained in RPMI 1640 medium containing 10% 
FCS, 2 mM L-glutamine, and 0.16 mg/mL gentamycin in at 37°C in 5% CO2 atmosphere. Cells 
were harvested at confluent state by treating with 0.5 g/L trypsin for 10 minutes. 
 
In vitro cytotoxicity assay  
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Cells were plated into 96 well tissue-culture plate in 200 µl culture medium (RPMI 1640, 10% 
FCS, 2 mM/mL L-glutamine, and 0.16 mg/mL gentamycin) with initial cell number of 104 
cells/well. Cells were treated with the unlabeled polypeptides dissolved in fresh culture medium 
at final concentrations of 6.25, 12.5, 25, 50 and 100 µg/mL concentrations. After 60 minutes 
incubation at 37°C cell viability was determined by MTT-assay. MTT at a final concentration of 
0.36 mg/mL was added to each well. After 3 hours incubation formazan crystals were dissolved 
in DMSO, and then absorbance was measured with ELISA-reader (Labsystems iEMS Reader) at 
λ=540 nm and 620 nm as reference wavelength. Cytotoxicity was expressed in the percentage of 
untreated control. Cytotoxic effect was calculated with the following equation:  
    
Cytotoxicity [%] = (1-ODtreated/ODcontrol)×100 
 
50 percent lethal concentration (LC50) was determined by performing a logistic fit on the data 
points using Microcal Origin 9.2 and the calculating X values at Y=50.  
 
Uptake of carboxyfluorescein-labeled polypeptides 
Cells were plated into 24-well tissue culturing plate (105 cells/well) 24 hours before the 
experiments. Cells were washed with serum free medium and then incubated with the solution of 
the Cf-labeled polypeptides dissolved in serum free RPMI 1640 at 0.1 µg/mL, 1 µg/mL, 10 
µg/mL, 50 µg/mL and 100 µg/mL concentration for 1 hour at 37°C or 4°C. In case of inhibition, 
cells were pre-treated with colchicine (10 µM) inhibitor of pinocytosis 31, MβCD (2.5 mM), 
inhibitor of caveole/lipid raft mediated endocytosis 32, EIPA (75 µM) 33 and cytochalasin D (5 
µg/mL) for inhibiting macropinocytosis 34, for 30 minutes followed by 1 hour incubation with the 
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Cf-polypeptides. Cells were then washed twice with PBS (0.1M, pH 7.4) and harvested with 0.5 
g/L trypsin (treated for 10 minutes). Cells were examined by flow cytometry on a BD LSR II 
flow cytometer. Data were recorded measuring 5000-10000 cells and fluorescence mean values 
were calculated. Statistical analysis of data was performed using Student’s t-test at the 95% 
confidence level.  
 
Study of the uptake by confocal laser scanning microscopy 
For the microscopic studies cells were cells were seeded onto Lab-Tek II 8-chamber Slide 
(Thermo Fisher Scientific, Waltham, MA, USA) with initial cell number of 3×104 cells/well 24 
hours prior to the experiment. Cells were treated with the Cf-labeled polypeptides in serum free 
RPMI 1640 medium for 1 hour. Extracellular fluorescence was quenched using 0.01 % trypan 
blue solution for 15 minutes at room temperature in the dark. Cells were washed twice with PBS 
(0.1 M pH 7.4) and then fixed with 4% paraformaldehyde in PBS (0.1 M pH 7.4) for 15 minutes 
at room temperature. Membrane structures were labeled with DiD perchlorate dissolved in 
DMSO at c= 40 µg/ml. Precipitated crystals of DiD were removed by washing with PBS (0.1 M 
pH 7.4).  Cells were studied with a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy, 
Jena, Germany), using its 63x oil immersion objective. Carboxyfluorescein was excited at λ=488 
nm and DiD at λ=530 nm. Pictures were edited with ImageJ software. 
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Abbreviations 
Abbreviations of amino acids and their derivatives follow the revised recommendation of the 
IUPAC-IUB Committee on Biochemical Nomenclature entitled "Nomenclature and Symbolism 
for Amino Acids and Peptides" (recommendations of 1983). Nomenclature of branched chain 
polypeptides is used in accordance with the recommended nomenclature of graft polypeptides 48. 
For the sake of brevity codes of branched chain polypeptides were constructed by us using the 
one-letter codes of amino acids. All amino acids are L configuration unless otherwise stated. The 
other abbreviation in this paper are the following -  Cf, 5(6)-carboxyfluorescein; CPP, cell 
penetrating peptide; DiD, 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine; DMF, N,N-
dimethylformamide; DMSO, dimethyl sulfoxide; EIPA, 5-(N-Ethyl-N-isopropyl)amiloride; FCS, 
fetal calf serum; HOBt, 1-hydroxy-bezotriazole; LC50, 50% lethal concentration; MβCD, methyl-
β-cyclodextrin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OPcp, 
pentachlorophenyl ester; PBS, phosphate-buffered saline; Pcp, pentachlorophenyl; Z: 
benzyloxycarbonyl; XiK, poly[Lys(Xi)]; AK, poly[Lys(DL-Alam)]; XAK, poly[Lys(Xi-DL-Alam)], 
AXK, poly[Lys(DL-Alam-Xi)] 
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